Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gene therapy rewire brain cells to ease Parkinson's?

NCT ID NCT07718659

Not yet recruiting Disease control Sponsor: Qianfoshan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This early trial tests a gene therapy called ZR001 in people with moderately advanced Parkinson's disease. ZR001 is injected into a brain region involved in movement, and a very low dose of an existing drug is then used to activate the therapy. The goal is to see if this approach is safe and can improve motor symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ZR001, a gene therapy that uses chemogenetics to control brain cells, plus ultra-low-dose clozapine to activate the therapy
What this could lead to
If successful, this could point toward a new way to control Parkinson's motor symptoms using a single gene therapy treatment.
What could go wrong
This is a very early, small phase 1 trial with only 6-8 participants. The approach is novel and unproven in humans, and risks include side effects from the injection or the activating drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system disorder movement disorder neurodegenerative disease Parkinson disease parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD) PARKINSONIAN DISORDERS

Contacts and locations

Locations

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.